Montelukast Tecnigen (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes from binding and triggering bronchoconstriction, airway edema, and inflammation. By inhibiting this pathway, the drug helps keep the airways open and reduces allergic inflammation.

The specific dose of Montelukast Tecnigen is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. Common adult regimens involve a once‑daily tablet, but exact strength and frequency must follow the prescriber’s order.

Montelukast is classified as Pregnancy Category B, indicating no evidence of risk in animal studies and limited human data; it should be used only if the potential benefit justifies any possible risk. Small amounts are excreted in breast milk, so nursing mothers should discuss continuation with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast offers an oral, non‑steroidal option that targets leukotriene‑mediated inflammation, whereas inhaled corticosteroids act directly on airway inflammation via glucocorticoid receptors. Both can be used for asthma control, but inhaled steroids are generally more potent for severe disease, while Montelukast is useful as add‑on therapy or for patients preferring oral administration.

Store Montelukast Tecnigen tablets at ambient temperature, preferably below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

Montelukast Tecnigen is taken orally, usually as a whole tablet with or without food, once daily in the evening. The exact timing and whether it should be taken with meals are determined by the prescribing clinician.

Serious adverse events include angioedema, severe skin reactions such as Stevens‑Johnson syndrome, eosinophilic pneumonia, hepatic injury, anaphylaxis, and neuropsychiatric effects like mood changes or suicidal thoughts. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. It should not be used as a rescue medication for acute asthma attacks, and patients with severe hepatic impairment should be evaluated carefully before initiation.